SCHEMBL5422658

SCHEMBL5422658

CNc1nc(NC2CCCCCC2)nc(N(Cc2ccc(OC)c(Cl)c2)C2CCN(C)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 7/20 0.43
EHMT1 Q9H9B1 5/20 0.43
BCL6 P41182 2/20 0.42
PDE5A O76074 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PDE4A P27815 1/20 0.40
BRD4 O60885 2/20 0.39
CREBBP Q92793 2/20 0.39
EP300 Q09472 1/20 0.39
KDM1A O60341 1/20 0.38
RCOR1 Q9UKL0 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4838191 0.82 EHMT2 (0.49) EHMT2EHMT1BCL6PDE5ASMN1; SMN2
SCHEMBL5032253 0.80 EHMT2 (0.47) EHMT2EHMT1BCL6PDE5ASMN1; SMN2
SCHEMBL4829075 0.77 BCL6 (0.54) EHMT2EHMT1BCL6SMN1; SMN2LMNA
SCHEMBL6919068 0.76 BCL6 (0.41) EHMT2EHMT1BCL6SMN1; SMN2PDE4A
SCHEMBL6016904 0.75 BCL6 (0.48) EHMT2BCL6BRD4LMNAMAPT
SCHEMBL4839209 0.75 EHMT2 (0.50) EHMT2EHMT1BCL6SMN1; SMN2KDM1A
SCHEMBL4838816 0.74 BCL6 (0.65) EHMT2EHMT1BCL6SMN1; SMN2LMNA
SCHEMBL5032475 0.73 EHMT2 (0.49) EHMT2EHMT1BCL6SMN1; SMN2KDM4E
Malonic Acid SCHEMBL4832223 0.73 BCL6 (0.49) EHMT2EHMT1BCL6SMN1; SMN2BRD4
SCHEMBL5038228 0.73 BCL6 (0.56) EHMT2EHMT1BCL6SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099874-A1 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099874-A1 Methods and compositions of novel triazine compounds AREG, TGFB1, PTGIS EHMT2 2905/4885EHMT1 2811/4885BCL6 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.